ZA200402753B - Methods for treating ocular neovascular diseases. - Google Patents
Methods for treating ocular neovascular diseases. Download PDFInfo
- Publication number
- ZA200402753B ZA200402753B ZA200402753A ZA200402753A ZA200402753B ZA 200402753 B ZA200402753 B ZA 200402753B ZA 200402753 A ZA200402753 A ZA 200402753A ZA 200402753 A ZA200402753 A ZA 200402753A ZA 200402753 B ZA200402753 B ZA 200402753B
- Authority
- ZA
- South Africa
- Prior art keywords
- vegf
- nucleic acid
- acid ligand
- aptamer
- eye
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 42
- 201000010099 disease Diseases 0.000 title claims description 32
- 238000000034 method Methods 0.000 title description 30
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 78
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 77
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 77
- 108091023037 Aptamer Proteins 0.000 claims description 70
- 238000002428 photodynamic therapy Methods 0.000 claims description 51
- 239000003504 photosensitizing agent Substances 0.000 claims description 43
- 238000002560 therapeutic procedure Methods 0.000 claims description 41
- 239000007924 injection Substances 0.000 claims description 37
- 238000002347 injection Methods 0.000 claims description 37
- 239000003446 ligand Substances 0.000 claims description 36
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 33
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 33
- 108020004707 nucleic acids Proteins 0.000 claims description 33
- 102000039446 nucleic acids Human genes 0.000 claims description 33
- 150000007523 nucleic acids Chemical class 0.000 claims description 33
- 206010029113 Neovascularisation Diseases 0.000 claims description 32
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 31
- 208000002780 macular degeneration Diseases 0.000 claims description 31
- 150000001875 compounds Chemical class 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 23
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 16
- 230000002411 adverse Effects 0.000 claims description 15
- 210000004204 blood vessel Anatomy 0.000 claims description 13
- 210000004127 vitreous body Anatomy 0.000 claims description 13
- 230000002159 abnormal effect Effects 0.000 claims description 11
- 238000011161 development Methods 0.000 claims description 11
- 150000004032 porphyrins Chemical class 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 10
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 238000001126 phototherapy Methods 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000000649 photocoagulation Effects 0.000 claims description 7
- 208000007135 Retinal Neovascularization Diseases 0.000 claims description 6
- 208000017442 Retinal disease Diseases 0.000 claims description 6
- 208000028867 ischemia Diseases 0.000 claims description 6
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims description 6
- 210000001525 retina Anatomy 0.000 claims description 6
- 206010038923 Retinopathy Diseases 0.000 claims description 5
- 201000000159 corneal neovascularization Diseases 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 5
- 201000011190 diabetic macular edema Diseases 0.000 claims description 5
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 5
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical group N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 claims description 4
- 206010055665 Corneal neovascularisation Diseases 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 4
- 102000053602 DNA Human genes 0.000 claims description 4
- 238000009792 diffusion process Methods 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 229920002477 rna polymer Polymers 0.000 claims description 4
- SIEXFRDYNDREBM-UHFFFAOYSA-N 2-[[2-[7-carboxy-3-(2-carboxyethyl)-17-ethenyl-12-ethyl-2,8,13,18-tetramethyl-2,3,23,24-tetrahydroporphyrin-5-yl]acetyl]amino]butanedioic acid Chemical compound N1C2=C(C)C(C=C)=C1C=C(N1)C(C)=C(CC)C1=CC(C(C)=C1C(O)=O)=NC1=C(CC(=O)NC(CC(O)=O)C(O)=O)C(C(CCC(O)=O)C1C)=NC1=C2 SIEXFRDYNDREBM-UHFFFAOYSA-N 0.000 claims description 3
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 claims description 3
- 102000004533 Endonucleases Human genes 0.000 claims description 3
- 108010042407 Endonucleases Proteins 0.000 claims description 3
- 108060002716 Exonuclease Proteins 0.000 claims description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 230000027455 binding Effects 0.000 claims description 3
- 230000003467 diminishing effect Effects 0.000 claims description 3
- ISVXIZFUEUVXPG-UHFFFAOYSA-N etiopurpurin Chemical compound CC1C2(CC)C(C(=O)OCC)=CC(C3=NC(C(=C3C)CC)=C3)=C2N=C1C=C(N1)C(CC)=C(C)C1=CC1=C(CC)C(C)=C3N1 ISVXIZFUEUVXPG-UHFFFAOYSA-N 0.000 claims description 3
- 102000013165 exonuclease Human genes 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 229940109328 photofrin Drugs 0.000 claims description 3
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960004293 porfimer sodium Drugs 0.000 claims description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- XFHNUTUVALSHOS-UHFFFAOYSA-N 21-hydroxy-5,10,15,20-tetraphenyl-23H-porphyrin-2,3,7-triol Chemical compound Oc1cc2nc1c(-c1ccccc1)c1c(O)c(O)c(c(-c3ccccc3)c3ccc(n3)c(-c3ccccc3)c3ccc([nH]3)c2-c2ccccc2)n1O XFHNUTUVALSHOS-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 description 40
- 238000011282 treatment Methods 0.000 description 36
- 239000000203 mixture Substances 0.000 description 29
- 230000004438 eyesight Effects 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 23
- 230000004304 visual acuity Effects 0.000 description 18
- 230000006872 improvement Effects 0.000 description 17
- 229940079593 drug Drugs 0.000 description 15
- 238000009472 formulation Methods 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 230000005855 radiation Effects 0.000 description 10
- 230000002207 retinal effect Effects 0.000 description 10
- 230000000007 visual effect Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 239000007943 implant Substances 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 230000033115 angiogenesis Effects 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- 206010054765 Anterior chamber inflammation Diseases 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000004410 intraocular pressure Effects 0.000 description 6
- 230000008728 vascular permeability Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 5
- 201000004569 Blindness Diseases 0.000 description 5
- 208000002177 Cataract Diseases 0.000 description 5
- 206010015958 Eye pain Diseases 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 description 4
- 230000003487 anti-permeability effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000004393 visual impairment Effects 0.000 description 4
- 206010010719 Conjunctival haemorrhage Diseases 0.000 description 3
- 206010010984 Corneal abrasion Diseases 0.000 description 3
- 208000028006 Corneal injury Diseases 0.000 description 3
- 206010015995 Eyelid ptosis Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000282560 Macaca mulatta Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000008383 Wilms tumor Diseases 0.000 description 3
- 229960002749 aminolevulinic acid Drugs 0.000 description 3
- 230000001772 anti-angiogenic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 201000008026 nephroblastoma Diseases 0.000 description 3
- 239000000906 photoactive agent Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 201000003004 ptosis Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000005598 Angioid Streaks Diseases 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 208000020446 Cardiac disease Diseases 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 208000033825 Chorioretinal atrophy Diseases 0.000 description 2
- 206010008790 Choroidal rupture Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 201000002563 Histoplasmosis Diseases 0.000 description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
- 208000037060 Hyalosis asteroid Diseases 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 208000010164 Multifocal Choroiditis Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010073286 Pathologic myopia Diseases 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 206010058990 Venous occlusion Diseases 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- 208000034699 Vitreous floaters Diseases 0.000 description 2
- 206010047661 Vitreous prolapse Diseases 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000011930 active peptic ulcer disease Diseases 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002137 anti-vascular effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000011970 concomitant therapy Methods 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000013534 fluorescein angiography Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 102000058223 human VEGFA Human genes 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 238000013532 laser treatment Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 208000018769 loss of vision Diseases 0.000 description 2
- 231100000864 loss of vision Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000007491 morphometric analysis Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001179 pupillary effect Effects 0.000 description 2
- 239000008175 ready-to-use sterile solution Substances 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 238000009121 systemic therapy Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 101150012579 ADSL gene Proteins 0.000 description 1
- 102100020775 Adenylosuccinate lyase Human genes 0.000 description 1
- 108700040193 Adenylosuccinate lyases Proteins 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024214 Lenticular opacities Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 206010038903 Retinal vascular occlusion Diseases 0.000 description 1
- 206010039729 Scotoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 208000034698 Vitreous haemorrhage Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 150000004036 bacteriochlorins Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000004155 blood-retinal barrier Anatomy 0.000 description 1
- 230000004378 blood-retinal barrier Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 150000004035 chlorins Chemical class 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000003683 corneal stroma Anatomy 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 150000004688 heptahydrates Chemical class 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000000222 hyperoxic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 235000015250 liver sausages Nutrition 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- -1 phthalocyanines Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 150000004033 porphyrin derivatives Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000004276 retinal vascularization Effects 0.000 description 1
- 230000004233 retinal vasculature Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012475 sodium chloride buffer Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000002301 subretinal fluid Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YNHJECZULSZAQK-UHFFFAOYSA-N tetraphenylporphyrin Chemical compound C1=CC(C(=C2C=CC(N2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3N2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 YNHJECZULSZAQK-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000005089 vacuolized cytoplasm Anatomy 0.000 description 1
- 230000006496 vascular abnormality Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- YTZALCGQUPRCGW-ZSFNYQMMSA-N verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 229940061392 visudyne Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33230401P | 2001-11-09 | 2001-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200402753B true ZA200402753B (en) | 2005-01-05 |
Family
ID=23297643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200402753A ZA200402753B (en) | 2001-11-09 | 2004-04-08 | Methods for treating ocular neovascular diseases. |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20030171320A1 (de) |
| EP (1) | EP1441743A4 (de) |
| JP (1) | JP2005511576A (de) |
| KR (1) | KR20050044372A (de) |
| CN (1) | CN1582156A (de) |
| AP (1) | AP1750A (de) |
| AR (1) | AR037307A1 (de) |
| BR (1) | BR0213975A (de) |
| CA (1) | CA2464007A1 (de) |
| CR (1) | CR7330A (de) |
| EA (1) | EA006746B1 (de) |
| EC (1) | ECSP045098A (de) |
| GE (1) | GEP20063755B (de) |
| HR (1) | HRP20040406A2 (de) |
| IL (1) | IL161327A0 (de) |
| IS (1) | IS7215A (de) |
| MA (1) | MA27145A1 (de) |
| MX (1) | MXPA04004363A (de) |
| NO (1) | NO20041882L (de) |
| OA (1) | OA12720A (de) |
| PL (1) | PL371929A1 (de) |
| RS (1) | RS35404A (de) |
| TN (1) | TNSN04081A1 (de) |
| TW (1) | TWI260327B (de) |
| WO (1) | WO2003039404A2 (de) |
| ZA (1) | ZA200402753B (de) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2714081C (en) * | 2000-02-10 | 2013-08-06 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
| US6942655B2 (en) * | 2001-11-13 | 2005-09-13 | Minu, Llc | Method to treat age-related macular degeneration |
| US6936043B2 (en) * | 2001-11-13 | 2005-08-30 | Minu, Llc | Method to treat age-related macular degeneration |
| EP1605847B1 (de) * | 2003-03-07 | 2009-09-16 | Board Of Regents, The University Of Texas System | Gegen antikörper gerichtete photodynamische therapie |
| CL2004001996A1 (es) * | 2003-08-08 | 2005-05-06 | Eyetech Pharmaceuticals Inc | Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion. |
| CN1934255B (zh) | 2003-08-27 | 2012-07-11 | 奥普索特克公司 | 用于治疗眼新血管疾病的组合治疗 |
| AU2004274026A1 (en) | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
| US7575321B2 (en) | 2003-10-30 | 2009-08-18 | Welch Allyn, Inc. | Apparatus and method of diagnosis of optically identifiable ophthalmic conditions |
| PT1682537E (pt) | 2003-11-05 | 2012-06-20 | Sarcode Bioscience Inc | Moduladores de adesão celular |
| US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| WO2005072701A1 (en) | 2004-01-20 | 2005-08-11 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
| EP1732571A4 (de) * | 2004-03-05 | 2009-09-09 | Archemix Corp | Kontrollierte modulierung der pharmakokinetik und bioverteilung von aptamer-therapeutika |
| US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US8147865B2 (en) | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| EP2484365B1 (de) * | 2004-06-04 | 2013-10-02 | The Scripps Research Institute | Zusammensetzungen und Verfahren zur Behandlung neovaskulärer Erkrankungen |
| EP1776474A2 (de) * | 2004-07-23 | 2007-04-25 | (Osi) Eyetech, Inc. | Detektion von oligonukleotiden durch zweifache hybridisierung |
| JP2006056807A (ja) * | 2004-08-18 | 2006-03-02 | Konica Minolta Medical & Graphic Inc | 光線力学療法製剤 |
| AU2012200865A1 (en) * | 2004-10-21 | 2012-03-29 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
| RS52539B (en) * | 2004-10-21 | 2013-04-30 | Genentech Inc. | METHOD FOR TREATMENT OF INTRAOCULAR NEOVASCULAR DISEASES |
| WO2006047716A2 (en) * | 2004-10-26 | 2006-05-04 | Bioresponse Llc | Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus associated disease |
| CA2588449A1 (en) * | 2004-11-24 | 2006-06-01 | Therakine Corporation | An implant for intraocular drug delivery |
| US20060134176A1 (en) * | 2004-12-22 | 2006-06-22 | Bausch & Lomb Incorporated | Pharmaceutical delivery system and method of use |
| US20060134174A1 (en) * | 2004-12-22 | 2006-06-22 | Bausch & Lomb Incorporated | Pharmaceutical delivery system and method of use |
| US20060134175A1 (en) * | 2004-12-22 | 2006-06-22 | Stephen Bartels | Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use |
| PL1848431T3 (pl) | 2005-02-09 | 2016-08-31 | Santen Pharmaceutical Co Ltd | Ciekłe formulacje do leczenia chorób lub stanów |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| AU2006227116A1 (en) * | 2005-03-21 | 2006-09-28 | Santen Pharmaceutical Co., Ltd. | Drug delivery systems for treatment of diseases or conditions |
| US20060293270A1 (en) * | 2005-06-22 | 2006-12-28 | Adamis Anthony P | Methods and compositions for treating ocular disorders |
| US20090281184A1 (en) * | 2005-09-27 | 2009-11-12 | Sapporo Medical University | Pharmaceutical for prevention and treatment of ophthalmic disease induced by in-crease in vasopermeability |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| JP2009525282A (ja) * | 2006-01-30 | 2009-07-09 | （オーエスアイ）アイテツク・インコーポレーテツド | 血管新生疾患の治療のための組み合わせ療法 |
| CN101605529B (zh) | 2006-02-09 | 2013-03-13 | 参天制药株式会社 | 稳定制剂及它们的制备和使用方法 |
| WO2007097961A1 (en) * | 2006-02-16 | 2007-08-30 | Massachusetts Eye & Ear Infirmary | Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage |
| US20070218007A1 (en) * | 2006-03-17 | 2007-09-20 | Allergan, Inc. | Ophthalmic visualization compositions and methods of using same |
| BRPI0709016A2 (pt) | 2006-03-23 | 2011-06-21 | Macusight Inc | formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular |
| PT2364691E (pt) * | 2006-06-16 | 2013-05-15 | Regeneron Pharma | Formulações antagonistas de vegf adequadas para administração intravitreal |
| US8668676B2 (en) * | 2006-06-19 | 2014-03-11 | Allergan, Inc. | Apparatus and methods for implanting particulate ocular implants |
| US20080097335A1 (en) * | 2006-08-04 | 2008-04-24 | Allergan, Inc. | Ocular implant delivery assemblies |
| WO2008103320A1 (en) * | 2007-02-16 | 2008-08-28 | Novacea, Inc. | Methods of treating ophthalmic disorders with anthraquinones |
| WO2008140051A1 (ja) * | 2007-05-11 | 2008-11-20 | Santen Pharmaceutical Co., Ltd. | 非麦角系の選択的ｄ２受容体アゴニストを有効成分として含有する後眼部疾患の予防又は治療剤 |
| US9125807B2 (en) | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
| MX2010004281A (es) | 2007-10-19 | 2010-09-10 | Sarcode Corp | Composiciones y metodos para el tratamiento de la retinopatia diabetica. |
| US8530189B2 (en) * | 2008-10-16 | 2013-09-10 | Kathleen Cogan Farinas | Sustained drug delivery system |
| CN102215875B (zh) * | 2008-10-16 | 2014-08-06 | 凯瑟琳·科根·法瑞纳斯 | 持续药物递送系统 |
| SG172126A1 (en) | 2008-12-16 | 2011-07-28 | Quadra Logic Tech Inc | Combination of photodynamic therapy and anti-vegf agents in the treatment of unwanted choroidal neovasculature |
| US8545554B2 (en) * | 2009-01-16 | 2013-10-01 | Allergan, Inc. | Intraocular injector |
| CN102333544A (zh) * | 2009-02-06 | 2012-01-25 | 通用医疗公司 | 治疗血管损伤的方法 |
| WO2011009020A2 (en) | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
| DK2524693T3 (da) * | 2010-01-14 | 2014-08-25 | Sanwa Kagaku Kenkyusho Co | Lægemiddel til forebyggelse eller behandling af lidelser ledsaget af okulær angiogenese og / eller forøget okulær vaskulær permeabilitet |
| US20130225603A1 (en) * | 2010-09-27 | 2013-08-29 | Serrata Llc | Mdm2 inhibitors for treatment of ocular conditions |
| CN103533950A (zh) | 2011-01-13 | 2014-01-22 | 瑞泽恩制药公司 | Vegf拮抗剂在治疗血管生成眼病中的用途 |
| JPWO2012105610A1 (ja) | 2011-02-02 | 2014-07-03 | 株式会社三和化学研究所 | 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬 |
| KR101303920B1 (ko) * | 2011-04-26 | 2013-09-05 | 서울대학교산학협력단 | 프로토포르피린 ＩＸ 구조를 갖는 화합물을 포함하는, 저산소상태 유도성인자1α 또는 혈관내피세포성장인자 과다 발현으로 기인하는 질병의 예방 및 치료에 유용한 조성물 |
| TW201406707A (zh) * | 2012-05-04 | 2014-02-16 | Acucela Inc | 用以治療糖尿病性視網膜病變及其他眼部疾病之方法 |
| AU2013100070B4 (en) * | 2012-07-03 | 2013-04-04 | Novartis Ag | Use of device |
| CN103721257B (zh) * | 2012-10-16 | 2016-12-21 | 无锡兆真辐射技术有限公司 | 光敏素催化分解过氧化氢系列药物 |
| ES2879430T3 (es) | 2012-11-15 | 2021-11-22 | Apellis Pharmaceuticals Inc | Análogos de compstatina de acción prolongada y composiciones y métodos relacionados |
| US10308687B2 (en) | 2013-03-15 | 2019-06-04 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| RU2527360C1 (ru) * | 2013-04-23 | 2014-08-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Способ комбинированного лечения ретиноваскулярного макулярного отека |
| BR112016000546A2 (pt) | 2013-07-12 | 2017-11-21 | Ophthotech Corp | métodos para tratar ou prevenir condições oftalmológicas |
| AU2014370404A1 (en) * | 2013-12-24 | 2016-07-07 | Novelmed Therapeutics, Inc. | Compositions and methods of treating ocular diseases |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2017062879A2 (en) | 2015-10-07 | 2017-04-13 | Apellis Pharmaceuticals, Inc. | Dosing regimens |
| CN108474039B (zh) | 2015-12-03 | 2022-06-07 | 雷杰纳荣制药公司 | 抗vegf剂在制备用于治疗新生血管性年龄相关性黄斑变性患者的药物中的用途 |
| EP3397276A4 (de) | 2015-12-30 | 2019-12-18 | Kodiak Sciences Inc. | Antikörper und konjugate davon |
| BR112019020955A2 (pt) | 2017-04-07 | 2020-05-05 | Apellis Pharmaceuticals Inc | regimes de dosagem e composições e métodos relacionados |
| DE102017008721A1 (de) | 2017-09-16 | 2019-03-21 | protectismundi GmbH | Verfahren und Vorrichtung zur Hochhausbrandbekämfpung |
| EP3758737A4 (de) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | Il-6-antikörper und fusionskonstrukte und konjugate davon |
| WO2019210097A1 (en) * | 2018-04-25 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Aptamers with stability, potency or half-life for enhanced safety and efficacy |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN113101530B (zh) * | 2021-04-14 | 2022-09-30 | 中国人民解放军陆军特色医学中心 | 一种通过无线充电激活玻璃体腔植入性发光二极管的系统 |
| KR20240121668A (ko) | 2023-02-01 | 2024-08-09 | 아주대학교산학협력단 | 염증성 눈질환의 예방 및 치료용 조성물 |
| WO2024243081A1 (en) * | 2023-05-19 | 2024-11-28 | The Trustees Of Columbia University In The City Of New York | Treating elevated intraocular pressure with nicotinamide |
| CN118108804B (zh) * | 2024-04-26 | 2024-06-25 | 山东大学 | 一种缺氧敏感功能化修饰的抗血管生成多肽、纳米胶束材料及其制备方法与应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770592A (en) * | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
| US5342348A (en) * | 1992-12-04 | 1994-08-30 | Kaplan Aaron V | Method and device for treating and enlarging body lumens |
| US5731294A (en) * | 1993-07-27 | 1998-03-24 | Hybridon, Inc. | Inhibition of neovasularization using VEGF-specific oligonucleotides |
| US5798349A (en) * | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
| WO1995024930A1 (en) * | 1994-03-14 | 1995-09-21 | Massachusetts Eye & Ear Infirmary | Use of green porphyrins in ocular diagnosis and therapy |
| JP3845469B2 (ja) * | 1996-02-21 | 2006-11-15 | 明治製菓株式会社 | 眼底の新生血管の閉塞に用いる投与剤 |
| US5756541A (en) * | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
| ATE318143T1 (de) * | 1996-10-25 | 2006-03-15 | Gilead Sciences Inc | Gefaesszellen wachstumsfaktor (vegf) nukleinsaureligand-komplexe |
| US6123923A (en) * | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
| US6117862A (en) * | 1998-10-09 | 2000-09-12 | Qlt, Inc. | Model and method for angiogenesis inhibition |
| AU2001227837A1 (en) * | 2000-01-12 | 2001-07-24 | Light Sciences Corporation | Novel treatment for eye disease |
| CA2714081C (en) * | 2000-02-10 | 2013-08-06 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
| CA2373237A1 (en) * | 2000-03-10 | 2001-09-20 | Insite Vision Incorporated | Methods and compositions for treating and preventing posterior segment ophthalmic disorders |
| HUP0300347A3 (en) * | 2000-03-24 | 2005-03-29 | Novartis Ag | Improved treatment of neovascularization |
| US6936043B2 (en) * | 2001-11-13 | 2005-08-30 | Minu, Llc | Method to treat age-related macular degeneration |
| US20060258629A1 (en) * | 2002-10-18 | 2006-11-16 | Freeman William R | Photodynamic therapy for ocular neovascularization |
-
2002
- 2002-11-08 KR KR1020047006990A patent/KR20050044372A/ko not_active Ceased
- 2002-11-08 CN CNA028219562A patent/CN1582156A/zh active Pending
- 2002-11-08 AP APAP/P/2004/003026A patent/AP1750A/en active
- 2002-11-08 TW TW091132890A patent/TWI260327B/zh not_active IP Right Cessation
- 2002-11-08 GE GE5563A patent/GEP20063755B/en unknown
- 2002-11-08 EA EA200400518A patent/EA006746B1/ru not_active IP Right Cessation
- 2002-11-08 WO PCT/US2002/035986 patent/WO2003039404A2/en active Application Filing
- 2002-11-08 MX MXPA04004363A patent/MXPA04004363A/es not_active Application Discontinuation
- 2002-11-08 JP JP2003541500A patent/JP2005511576A/ja active Pending
- 2002-11-08 PL PL02371929A patent/PL371929A1/xx not_active Application Discontinuation
- 2002-11-08 US US10/291,091 patent/US20030171320A1/en not_active Abandoned
- 2002-11-08 EP EP02802885A patent/EP1441743A4/de not_active Withdrawn
- 2002-11-08 IL IL16132702A patent/IL161327A0/xx unknown
- 2002-11-08 BR BR0213975-8A patent/BR0213975A/pt not_active IP Right Cessation
- 2002-11-08 CA CA002464007A patent/CA2464007A1/en not_active Abandoned
- 2002-11-08 RS YU35404A patent/RS35404A/sr unknown
- 2002-11-08 OA OA1200400130A patent/OA12720A/en unknown
- 2002-11-11 AR ARP020104328A patent/AR037307A1/es unknown
-
2004
- 2004-02-25 US US10/786,491 patent/US20040167091A1/en not_active Abandoned
- 2004-04-07 IS IS7215A patent/IS7215A/is unknown
- 2004-04-08 ZA ZA200402753A patent/ZA200402753B/en unknown
- 2004-04-29 MA MA27662A patent/MA27145A1/fr unknown
- 2004-04-30 CR CR7330A patent/CR7330A/es not_active Application Discontinuation
- 2004-05-07 HR HR20040406A patent/HRP20040406A2/hr not_active Application Discontinuation
- 2004-05-07 NO NO20041882A patent/NO20041882L/no not_active Application Discontinuation
- 2004-05-07 TN TNP2004000081A patent/TNSN04081A1/fr unknown
- 2004-05-07 EC EC2004005098A patent/ECSP045098A/es unknown
-
2006
- 2006-07-24 US US11/491,818 patent/US20070027101A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AP1750A (en) | 2007-06-23 |
| ECSP045098A (es) | 2004-07-23 |
| EA200400518A1 (ru) | 2004-12-30 |
| AP2004003026A0 (en) | 2004-06-30 |
| IL161327A0 (en) | 2004-09-27 |
| TW200302226A (en) | 2003-08-01 |
| CR7330A (es) | 2005-06-15 |
| TNSN04081A1 (fr) | 2006-06-01 |
| TWI260327B (en) | 2006-08-21 |
| WO2003039404A2 (en) | 2003-05-15 |
| HRP20040406A2 (en) | 2005-02-28 |
| EA006746B1 (ru) | 2006-04-28 |
| US20030171320A1 (en) | 2003-09-11 |
| EP1441743A2 (de) | 2004-08-04 |
| CA2464007A1 (en) | 2003-05-15 |
| CN1582156A (zh) | 2005-02-16 |
| NO20041882L (no) | 2004-05-07 |
| US20040167091A1 (en) | 2004-08-26 |
| KR20050044372A (ko) | 2005-05-12 |
| AR037307A1 (es) | 2004-11-03 |
| RS35404A (en) | 2006-10-27 |
| IS7215A (is) | 2004-04-07 |
| US20070027101A1 (en) | 2007-02-01 |
| OA12720A (en) | 2006-06-27 |
| EP1441743A4 (de) | 2009-02-25 |
| MXPA04004363A (es) | 2005-05-16 |
| GEP20063755B (en) | 2006-02-27 |
| JP2005511576A (ja) | 2005-04-28 |
| WO2003039404A3 (en) | 2004-02-12 |
| BR0213975A (pt) | 2005-05-10 |
| MA27145A1 (fr) | 2005-01-03 |
| PL371929A1 (en) | 2005-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20030171320A1 (en) | Methods for treating ocular neovascular diseases | |
| AU2002230567B2 (en) | Compositions for treatment of ocular neovascularization and neural injury | |
| Eyetech Study Group | Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results | |
| US20060293270A1 (en) | Methods and compositions for treating ocular disorders | |
| US20070027102A1 (en) | Methods and compositions for treating macular degeneration | |
| AU2002230567A1 (en) | Compositions for treatment of ocular neovascularization and neural injury | |
| EP2524693B1 (de) | Pharmazeutikum zur verhinderung oder behandlung von durch okulare angiogenese und/oder erhöhte augengefässdurchlässigkeit begleiteten erkrankungen | |
| US20060166956A1 (en) | Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration | |
| AU2002363336A1 (en) | Methods for treating ocular neovascular diseases | |
| AU2006201701B2 (en) | Methods and compositions for treatment of ocular neovascularization and neural injury | |
| Rezaei et al. | Age-Related Macular Degeneration Drug Delivery | |
| Jiang et al. | Clinical Observation of Micropulse Laser Combined with Conbercept in the Treatment of Neovascular Age-related Macular Degeneration with Pigment Epithelial Detachment (PED) |